Alternative & Natural Medicine: what actually checks out
Two very different things get called "natural medicine" — rigorously researched complementary approaches, and personality-driven commentary. We keep them clearly separated.
What to know: The National Center for Complementary and Integrative Health (NCCIH) — the federal government's lead research agency in this exact space — draws an explicit line between "complementary" approaches with real scientific backing and unproven "alternative" claims. The center was renamed from NCCAM to NCCIH in 2014 specifically to reinforce the position that evidence-based complementary therapies should be integrated alongside conventional medicine, not marketed as a replacement for it. NCCIH's own research covers natural products (dietary supplements, plant-based products, probiotics) and mind-body approaches (yoga, meditation, massage therapy, mindfulness-based stress reduction) — a real, funded federal research program, not a fringe operation. This page keeps that research separate from personality-driven radio and podcast commentary, which is popular and often draws on real nutritional science, but isn't independently verified the same way and sometimes conflicts with mainstream medical consensus.
NCCIH's actual research priorities for complementary medicine
The center's current strategic plan focuses on five objectives: advancing fundamental science, researching the whole person rather than isolated symptoms, studying disease prevention and symptom management, building the research workforce in this field, and — critically — providing objective, evidence-based information to the public rather than promotional claims.
"Herbs at a Glance" — NCCIH's own plain-language evidence reviews
NCCIH publishes free monographs on more than 50 herbs and natural products, each covering general use, the actual evidence-based recommendation, and known risks or drug interactions — a genuinely useful starting point before trusting any supplement claim you hear elsewhere.
The honest state of the evidence — the good and the bad, not a sales pitch: These four categories are at very different stages of scientific validation, and treating them as equally "proven" would be misleading. Psilocybin and MDMA have real Phase 3 clinical trial data and FDA engagement, but also a real 2024 rejection. CBD has genuine peer-reviewed support for pain and certain conditions, while THC carries real documented psychiatric risk. Peptides like BPC-157 have almost no human clinical data despite a booming market. NAD+ IV therapy — one of the most heavily marketed wellness trends right now — has literally zero direct human outcome trials behind it. This page is informational only, not medical advice or a recommendation to use any of these substances.
Psilocybin & MDMA: real progress, and a real rejection
The promising: in the Phase 3 trial for MDMA-assisted therapy, 67% of participants no longer met PTSD diagnostic criteria after three sessions — durable at 67% after one year and 74% after nearly four years. Psilocybin holds FDA "breakthrough therapy" designations (2018, 2019) for treatment-resistant depression, and Compass Pathways is targeting a Q4 2026 FDA submission for its psilocybin treatment. The caution: the FDA rejected Lykos Therapeutics' MDMA therapy for PTSD in August 2024 by a 9-2 advisory committee vote, citing "functional unblinding" — participants in these trials can usually tell whether they received the real drug, which biases self-reported results. Both remain Schedule I controlled substances, not legally available outside clinical trials.
CBD vs. THC: genuinely different risk profiles, not interchangeable
The promising: a systematic review of 40 studies found "sufficient clinical and preclinical evidence" for CBD alone in pain treatment, with real mechanisms (TRPV-1, 5-HT1A, CB1 receptor activity). A randomized trial in children found 49% "much or very much improved" on whole-plant CBD:THC versus 21% on placebo. The caution: THC — not CBD — was shown to worsen both psychotic symptoms and cognitive function in people with schizophrenia, while CBD showed antipsychotic, neuroprotective potential in the same review. Even CBD's best-supported use, chronic neuropathic pain, shows only a small effect (0.5-1.0 points on a 0-10 pain scale) with increased dropout rates from side effects.
Peptides (BPC-157 and similar): a real regulatory fight, thin human evidence
The caution — the dominant story here: nearly all BPC-157 data comes from animal studies and a single research group; a 2015 human trial was canceled before results were published. FDA's own scientists recommended against wider compounding access due to insufficient safety data — yet in July 2026, an FDA advisory committee voted in favor of wider access to six peptides anyway, a genuine internal regulatory conflict. Because these peptides work by stimulating tissue growth, some researchers have raised real cancer-risk concerns. None are FDA-approved; most are legally sold only as "research chemicals not for human consumption." Contrast: legitimate peptide-class drugs do exist and get real trials — retatrutide, a GLP-1 peptide, is in genuine Phase 3 trials with Eli Lilly, targeting approval in 2027-2028.
NAD+ IV therapy: a wellness trend with zero direct outcome trials
A February 2026 PRISMA-guided systematic review found 113 eligible studies on NAD+-related compounds — but no eligible outcomes trials tested IV or intramuscular NAD+ specifically for anti-aging or wellness, despite that being exactly how it's marketed and sold at wellness clinics. Rodent studies often show metabolic and inflammatory improvements, but human translation remains unclear. The review's own conclusion: NAD+ precursors are "best framed as experimental adjuncts rather than established anti-aging therapies," and patients should be counseled that NAD+ augmentation "is not a substitute for interventions with proven benefit."
This page is informational and not medical advice. Talk to a qualified doctor before starting any supplement or making changes to prescribed treatment, especially content sourced from radio/podcast commentary rather than peer-reviewed research.